Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Look at the Safety of NNC0363-0845 in Healthy People and People With Type 1 Diabetes

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04569994
Recruitment Status : Recruiting
First Posted : September 30, 2020
Last Update Posted : April 29, 2021
Sponsor:
Information provided by (Responsible Party):
Novo Nordisk A/S

Brief Summary:

This study is investigating the safety and tolerability of the new investigational product NNC0363-0845, its concentrations in the blood and its effect on the blood sugar for the treatment of diabetes. The study consists of 3 parts. The first part of the study is conducted in healthy people, while the second part involves people with type 1 diabetes (T1D). Part 3 of this trial involves also people with T1D.

The study will test how NNC0363-0845 is tolerated by the body, how it is taken up in the blood, how long it stays there and how much the blood sugar is lowered. Healthy volunteers will either get NNC0363-0845 or placebo - which treatment is decided by chance. Participants with type 1 diabetes will either get NNC0363-0845 or insulin degludec (Tresiba®), also decided by chance. It is the first time that NNC0363-0845 is tested in humans. Participants will get one dose of NNC0363-0845 or placebo or insulin degludec injected into their left thigh. Participation in the study will last for up to 6 weeks. There will be one Informed Consent visit and 6 clinic visits with the study doctor. Healthy volunteers will have blood sampling to measure blood sugar and the concentration of the investigational product in the blood. Participants with type 1 diabetes will have a clamp experiment where the blood sugar is measured and controlled for up to 42 hours.

For Part 3, the total duration of the trial for each individual is expected to be approximately 3-9 weeks.

Participants cannot be in the study if the study doctor thinks that there are risks for their health. Women can only take part in the study if they are of non-child bearing potential.


Condition or disease Intervention/treatment Phase
Healthy Volunteers Diabetes Mellitus, Type 1 Drug: NNC0363-0845 Drug: Placebo (NNC0363-0845) Drug: Insulin degludec Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 78 participants
Allocation: Randomized
Intervention Model: Sequential Assignment
Intervention Model Description:

Part 1 will be a placebo-controlled trial in healthy subjects; Part 2 will be an active-controlled trial in subjects with T1D.

Part 3 of this trial, will be an open-label, two-period cross-over, randomised, single dose trial in subjects with T1D.

Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description: Sponsor staff involved in the clinical trial is masked according to company standard procedures.
Primary Purpose: Treatment
Official Title: A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous NNC0363-0845 in Healthy Subjects and in Subjects With Type 1 Diabetes
Actual Study Start Date : September 30, 2020
Estimated Primary Completion Date : July 16, 2021
Estimated Study Completion Date : July 16, 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Diabetes Type 1

Arm Intervention/treatment
Experimental: Part 1
Healthy volunteers will receive either NNC0363-0845 or placebo
Drug: NNC0363-0845
A single dose administered s.c. (subcutaneously, under the skin)

Drug: Placebo (NNC0363-0845)
A single dose administered s.c.

Experimental: Part 2
Participants with T1D will receive either NNC0363-0845 or insulin degludec
Drug: NNC0363-0845
A single dose administered s.c. (subcutaneously, under the skin)

Drug: Insulin degludec
A single dose administered s.c.

Experimental: Part 3
Participants with T1D will receive NNC0363-0845
Drug: NNC0363-0845
A single dose administered s.c. (subcutaneously, under the skin)




Primary Outcome Measures :
  1. Number of treatment-emergent adverse events (AEs) [ Time Frame: Part 1 and 2: From trial product administration at Visit 2, day 1 until completion of post treatment end-of-trial visit at Visit 6, day 10 ]
    Number of events

  2. Number of treatment-emergent adverse events (AEs) [ Time Frame: Part 3: From trial product administration at Visit 2, day 1 until completion of post treatment end-of-trial visit at Visit 4 (up to 33 days after Visit 2, day 1) ]
    Number of events


Secondary Outcome Measures :
  1. Number of treatment-emergent hypoglycaemic episodes [ Time Frame: Part 1 and 2 From trial product administration at Visit 2, day 1 until completion of post treatment end-of-trial visit at Visit 6, day 10 ]
    Number of episodes

  2. Number of treatment-emergent hypoglycaemic episodes [ Time Frame: Part 3: From trial product administration at Visit 2, day 1 until completion of post treatment end-of-trial visit at Visit 4 (up to 33 days after Visit 2, day 1) ]
    Number of episodes

  3. Area under the serum NNC0363-0845 concentration-time curve from 0 to infinity after a single dose [ Time Frame: Part 1 and 2 From 0 hours until last measurement time after trial product administration (Visit 2, day 1) ]
    pmol*h/L

  4. Area under the serum NNC0363-0845 concentration-time curve from 0 to infinity after a single dose [ Time Frame: Part 3: From 0 hours until last measurement time after trial product administration (Visit 2, day 1 and Visit 3, day 1) ]
    pmol*h/L

  5. Maximum observed serum NNC0363-0845 concentration after a single dose [ Time Frame: Part 1 and 2 From 0 hours until last measurement time after trial product administration (Visit 2, day 1) ]
    pmol/L

  6. Maximum observed serum NNC0363-0845 concentration after a single dose [ Time Frame: Part 3: From 0 hours until last measurement time after trial product administration (Visit 2, day 1 and Visit 3, day 1) ]
    pmol/L



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

Part 1 (healthy subjects):

  • Male subject or female subject of non-child bearing potential. Non-child bearing potential being defined as surgically sterilised (i.e. documented hysterectomy, bilateral salpingectomy or bilateral oophorectomy) or being postmenopausal (defined as no menses for 12 months without an alternative medical cause) prior to the day of screening.
  • Aged 18-55 years (both inclusive) at the time of signing informed consent.
  • Considered to be generally healthy based on the medical history, physical examination, and the results of vital signs, electrocardiogram and clinical laboratory tests performed during the screening visit, as judged by the investigator.

Part 2 and 3 (subjects with type 1 diabetes mellitus):

  • Male subject or female subject of non-child bearing potential. Non-child bearing potential being defined as surgically sterilised (i.e. documented hysterectomy, bilateral salpingectomy or bilateral oophorectomy) or being postmenopausal (defined as no menses for 12 months without an alternative medical cause) prior to the day of screening.
  • Aged 18-55 years (both inclusive) at the time of signing informed consent.
  • Diagnosed with type 1 diabetes mellitus 1 year or more prior to the day of screening.
  • Glycated haemoglobin (HbA1c) equal to or below 8.5%.
  • Fasting C-peptide below 0.30 nmol/L.
  • Considered to be generally healthy (except for type 1 diabetes mellitus and sequelae of diabetes which may only be of mild severity) based on the medical history, physical examination, and the results of vital signs, electrocardiogram and clinical laboratory tests performed during the screening visit, as judged by the investigator

Exclusion Criteria:

Part 1 (healthy subjects) Part 2 and Part 3 (subjects with type 1 diabetes mellitus):

- Male of reproductive age who or whose partner(s) is not using an adequate contraceptive method (adequate contraceptive measures as required by local regulation or practice). Adequate contraceptive measures include that the male subject uses a condom during intercourse and that the partner practices adequate contraception (risk of pregnancy must be lower than 1%). In addition, subjects must not donate sperm for the duration of the trial.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04569994


Contacts
Layout table for location contacts
Contact: Novo Nordisk (+1) 866-867-7178 clinicaltrials@novonordisk.com

Locations
Layout table for location information
Germany
Novo Nordisk Investigational Site Recruiting
Mainz, Germany, 55116
Sponsors and Collaborators
Novo Nordisk A/S
Investigators
Layout table for investigator information
Study Director: Clinical Transparency and Medical Writing Office (1452) Novo Nordisk A/S
Layout table for additonal information
Responsible Party: Novo Nordisk A/S
ClinicalTrials.gov Identifier: NCT04569994    
Other Study ID Numbers: NN1845-4598
U1111-1244-4315 ( Other Identifier: World Health Organization (WHO) )
2019-004658-27 ( Registry Identifier: European Medicines Agency (EudraCT) )
First Posted: September 30, 2020    Key Record Dates
Last Update Posted: April 29, 2021
Last Verified: April 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus
Diabetes Mellitus, Type 1
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Autoimmune Diseases
Immune System Diseases
Insulin
Hypoglycemic Agents
Physiological Effects of Drugs